POLDIP3

Across TCGA pan-cancer cohorts, POLDIP3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLDIP3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLDIP3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated POLDIP3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where POLDIP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.974	0.771	.002	17	view →
HNSC	OS	Quartile	IV	0.684	0.964	.008	12	view →
LSCC	OS	Quartile	All	0.968	0.715	.005	8	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
CCRCC	DFS	Tertile	III,IV	0.765	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POLDIP3–PDAC (OS)

Open the PDAC breakdown →